Stimulants are the first line of therapy for attention-deficit/hyperactivity disorder
(ADHD) in children 6 years and older. Vyvanse is a long acting prodrug stimulant with
well-established safety, tolerability and efficacy, when compared to other stimulants
such as amphetamine and methylphenidate, and non-stimulants such as atomoxetine, guanfacine,
and clonidine. Treatment related adverse events for stimulant drugs in all age groups
have been reported in great detail, but there is limited data available in the literature
regarding withdrawal symptoms from acute cessation or dose reduction in children.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to British Journal of Oral and Maxillofacial SurgeryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Identification
Copyright
© 2019 Published by Elsevier Inc.
